Slate Gray Metallic is being dropped from the 2025 Chevy Silverado 1500 exterior paint palette, with the last time to order being on the week of February 3rd.

The Thunderstorm Gray exterior paint color is only available to order for a few more days on the 2025 GMC Sierra 1500, on the ...

These 10 iconic pickup trucks from the 2000s and 2010s changed the truck world and came to define what a pickup truck is and ...

The mid-size GMC Canyon is an affordable truck at the base level, but it can change exponentially depending on the trim and options. Fancy it up with the $53,595 Canyon Denali, or go balls to the ...

Engine, Vortec 6.0L Variable Valve Timing V8 SFI E85-compatible, FlexFuel capable of running on unleaded or up to 85% ethanol (360 hp [268.4 kW] @ 5400 rpm, 380 lb-ft of torque [515.0 N-m] @ 4200 ...

I was tasked with stomping around Pennsylvania and Maryland in a 2025 GMC Hummer 3X SUV. The EV Hummer first launched as a truck, reminiscent of the Chevy Avalanche and Cadillac Escalade EXT.

The GMC Sierra Denali ... and the Ram 1500, all of which have an upmarket trim level that delivers luxury features and appointments. The Sierra Denali's mechanical twin, the Chevy Silverado ...

The e-commerce giant said the trucks will start joining its network later this year and will be deployed on "high-mileage routes" across Amazon's middle-mile network between fulfilment centres ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing several programs—and an executive—from Denali Therapeutics.

A new company is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug candidates and raising money from one of its original investors. The biotech ...

Tenvie Therapeutics has launched with $200 million and a clutch of assets from Denali Therapeutics to go after neurological diseases with small molecules. Backed by ARCH Venture Partners, F-Prime ...

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all taken a hit. Massachusetts General Hospital found neither AbbVie and ...